Provided by Tiger Trade Technology Pte. Ltd.

Entera Bio Ltd.

2.66
+0.16006.40%
Post-market: 2.62-0.0400-1.50%17:05 EDT
Volume:1.58M
Turnover:4.19M
Market Cap:460.18M
PE:-7.52
High:2.72
Open:2.51
Low:2.51
Close:2.50
52wk High:4.20
52wk Low:0.9100
Shares:173.00M
Float Shares:139.65M
Volume Ratio:2.57
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3536
EPS(LYR):-0.2476
ROE:-138.92%
ROA:-45.98%
PB:63.33
PE(LYR):-10.74

Loading ...

Top Premarket Decliners

MT Newswires Live
·
Yesterday

Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

GlobeNewswire
·
Oct 08

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)

TIPRANKS
·
Oct 07

Entera Bio Appoints Ex-Gilead Executive Laura Hamill to Board of Directors

Reuters
·
Oct 06

Guggenheim Initiates Entera Bio at Buy With $11 Price Target

MT Newswires Live
·
Sep 25

Guggenheim starts Entera with Buy on N-tab platform potential

TIPRANKS
·
Sep 25

Entera Bio Ltd : Guggenheim Initiates Coverage with Buy Rating; Price Target $11

THOMSON REUTERS
·
Sep 25

Entera Bio Receives New Overweight Rating From Cantor Fitzgerald (NASDAQ: ENTX)

TIPRANKS
·
Sep 23

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 23

Entera Bio Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 22

Entera Bio initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Sep 22

Entera Bio Price Target Announced at $9.00/Share by Leerink Partners

Dow Jones
·
Sep 18

Entera Bio Ltd : Leerink Partners Initiates Coverage with Outperform Rating; Target Price $9

THOMSON REUTERS
·
Sep 18

Correction: Entera to Participate in Upcoming Fall Investor Conferences

GlobeNewswire
·
Aug 27

Entera Bio CEO Toledano Joins Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Aug 27

Entera Bio Files Form 3 for Chief Medical Officer Riccardo Paolo Camisasca

Reuters
·
Aug 21

Entera Bio Names Riccardo Paolo Camisasca Chief Medical Officer

Reuters
·
Aug 18

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

GlobeNewswire
·
Aug 18

Israel's Camtek Q2 Revenue Beats on Increased AI Compute Demand

Reuters
·
Aug 10

Israel's Perion Q2 Revenue Tops Estimates on Retail Media Growth

Reuters
·
Aug 10